Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
58-32-2
Molecular formula
C24H40N8O4
Molecular weight
504.6 g/mol
Drug class
Antiplatelet and vasodilatorphosphodiesterase inhibitor and adenosine uptake inhibitor
Mechanism of action
Inhibits platelet phosphodiesterases and cellular adenosine uptake, increasing intraplatelet cAMP and extracellular adenosine, thereby reducing platelet aggregation and producing vasodilatory effects.
Indications / reported uses
Prevention of thromboembolic complications after prosthetic heart valve replacement in combination with an oral anticoagulant under the product-specific indication
In combination with aspirin as extended-release dipyridamole for secondary stroke prevention in selected patients with prior ischaemic stroke or transient ischaemic attack; intravenous dipyridamole has a separate myocardial perfusion imaging indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Dipyridamole Environmental Risk Assessment (ERA) (the Dipyridamole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.